Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.

Chemotherapy

Volumn 50, Issue 4, 2004, Pages 202-210

  Drago, Lorenzo ^a   De Vecchi, Elena ^a   Nicola, Lucia ^a   Colombo, Alberto ^a   Guerra, Anna ^a   Gismondo, Maria Rita ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Lactams; Acinetobacter spp.; Aminoglycosides; Fluoroquinolones; Pseudomonas aeruginosa; Synergy, antibiotic

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STATISTICAL SIGNIFICANCE;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA;

EID: 8344290335     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081033     Document Type: Article

References (28)

1. Hoban DJ, Bouchillon S, Johnson JL, Zhanel GC, Butler DL, Miller LA, Poupard JA, the Gemifloxacin Surveillance Study Research Group: Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Eur J Clin Microbiol Infect Dis 2001;20:814-819.
2. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley I, Sahm DF: Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents 2002;19:21-31.
3. MacGowan, AP, Wotton M, Holt A: The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999;43:345-349.
4. Bergogne-Berezin E: The increasing role of Acinetobacter species as nosocomial pathogens. Curr Infect Dis Rep 2001;3:440-444.
5. Chastre J, Trouillet JL: Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 2000;15:287-298.
6. Harris A, Torres-Viera C, Venkataraman L, De Girolami P, Samore M, Carmeli Y: Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128-1133.
7. Waterer GW, Wunderink RG: Increasing threat of Gram-negative bacteria. Crit Care Med 2001;29(suppl 4):N75-N81.
8. Korvick JA, Yu VL: Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;35:2167-2172.
9. Lynch JP 3rd: Hospital-acquired pneumonia: Risk factors, microbiology, and treatment. Chest 2001;119(suppl 2):373S-384S.
10. Eliopoulos GM: Synergism and antagonism. Infect Dis Clin North Am 1989;3:399-406.
11. Committee of the Scientific Assembly on Microbiology, Tuberculosis and Pulmonary Infections: Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996;153:1711-1725.
12. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, Wu SC, Fowler C, Morgan N, Kahn JB: Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study. Clin Ther 2003;25:485-506.
13. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement M 100-S 11. Villanova, NCCLS, 2001.
14. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID): EUCAST Definitive Document E. Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000;6:503-508.
15. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC: Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother 1997;41:1073-1076.
16. Marques MB, Brookings ES, Moser SA, Sonke PB, Waites KB: Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997;41:881-885.
17. Song W, Woo HJ, Kim JS, Lee KM: In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003;21:8-12.
18. Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA: In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy 2003;49:44-48.
19. Mayer I, Nagy E: Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 1999;43:651-657.
20. Pendland SL, Messick CR, Jung R: In vitro synergy testing of levofloxacin, ofloxacin and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002;42:75-78.
21. Visalli MA, Jacobs MR, Appelbaum PC: Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998;42:953-955.
22. Erdem I, Kaynar-Tascioglu J, Kaya B, Goktas P: The comparison of the in vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Int J Antimicrob Agents 2002;20:384-386.
23. Gimeno C, Borja J, Navarro D, Valdes L, Garcia-Barbal J, Garcia de Lomas J: In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections. Chemotherapy 1998;44:94-98.
24. Cappelletty DM, Rybak MJ: Comparison of methodologies for synergism testing of drugs combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996;40:677-683.
25. Burgess DS, Nathisuwan S: Cefepime, piperacillin/ tazobactam, gentamicin, ciprofloxacin and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002;44:35-41.
26. Baltch AL, Smith RP: Combinations of antibiotics against Pseudomonas aeruginosa. Am J Med 1985;79:8-16.
27. Hallander HO, Dornbursch K, Gezelius L, Jacobson K, Karlsson I: Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: Interaction index and killing curve method. Antimicrob Agents Chemother 1982;22:743-752.
28. Miller MH, Feinstein SA, Chow RT: Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987;31:108-110.